The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
Issued Date
2023-01-01
Resource Type
ISSN
10428194
eISSN
10292403
Scopus ID
2-s2.0-85141135045
Pubmed ID
36282671
Journal Title
Leukemia and Lymphoma
Volume
64
Issue
2
Start Page
261
End Page
272
Rights Holder(s)
SCOPUS
Bibliographic Citation
Leukemia and Lymphoma Vol.64 No.2 (2023) , 261-272
Suggested Citation
Alomari M., Kunacheewa C., Manasanch E.E. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma. Leukemia and Lymphoma Vol.64 No.2 (2023) , 261-272. 272. doi:10.1080/10428194.2022.2133540 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/82339
Title
The role of soluble B cell maturation antigen as a biomarker in multiple myeloma
Author(s)
Author's Affiliation
Other Contributor(s)
Abstract
Currently used stratification models in myeloma precursor disease as well as staging systems and response criteria in myeloma have limitations including failure to identify functionally high-risk myeloma patients. B-cell maturation antigen, a transmembrane glycoprotein required for long-lived plasma cells, is specific and expressed by myeloma cells. When it sheds from the surface of myeloma cells it can be measured in the blood as serum (sBCMA) and correlated with clinical outcomes in myeloma precursor disease as well as in active myeloma. We performed a literature review using PubMed and found 825 articles since 1992 of which any articles related to sBCMA were reviewed. These studies show the potential of sBCMA to become an important biomarker in myeloma. Here, we describe the potential advantages of sBCMA in the biology, diagnosis, prognosis, and surveillance of myeloma, while also reviewing the challenges that lie ahead before it can be implemented as a clinical tool.